The importance of lung volumes in the investigation of heavy smokers;Place de la distension pulmonaire dans l'explorationdes gros fumeurs de cigarettes

Revue des Maladies Respiratoires

Volumn 31, Issue 1, 2014, Pages 29-40

  Ben Saad, H ^a,b   Ben Amor, L ^a   Ben Mdalla, S ^a   Ghannouchi, I ^a,b   Ben Essghair, M ^a   Sfaxi, R ^c   Garrouche, A ^d   Rouatbi, N ^e   Rouatbi, S ^a,b  

^a Service de Physiologie et des Explorations Fonctionnelles   (Tunisia)

^b UNIVERSITY OF SOUSSE   (Tunisia)

^c Centre de Sante de Base de Sousse   (Tunisia)

^d Service de Pneumologie   (Tunisia)

^e FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

COPD; Diagnosis; Hyperinflation; Plethysmography; Reversibility

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERINFLATION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PLETHYSMOGRAPHY; RESIDUAL VOLUME; SMOKING; AGED; BPCO; DIAGNOSIS; DIAGNOSTIC; DISTENSION PULMONAIRE; LONGITUDINAL STUDY; LUNG; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PLÉTHYSMOGRAPHIE; PREDICTIVE VALUE; REVERSIBILITY; RÉVERSIBILITÉ; SEVERITY OF ILLNESS INDEX; TOBACCO DEPENDENCE;

BPCO; COPD; DIAGNOSIS; DIAGNOSTIC; DISTENSION PULMONAIRE; HYPERINFLATION; PLETHYSMOGRAPHY; PLÉTHYSMOGRAPHIE; REVERSIBILITY; RÉVERSIBILITÉ;

ADULT; AGED; HUMANS; LONGITUDINAL STUDIES; LUNG; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; TOBACCO USE DISORDER;

EID: 84902597485     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.05.009     Document Type: Article

References (67)

1. Celli BR, MacNee W, ATS/ERS task force. Standards for the diag-nosis and treatment of patients with COPD: a summary of theATS/ERS position paper. Eur Respir J 2004;23:932-46
2. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for thediagnosis, management and prevention of chronic obstructivepulmonary disease, GOLD executive summary. Am J Respir CritCare Med 2013;187:347-65
3. Société de pneumologie de langue française. Recommanda-tion pour la pratique clinique : prise en charge de la BPCO.Définitions, classification, mortalité et facteurs pronostiques.Traitement pharmacologique incluant le sevrage tabacolo-gique. Réhabilitation du malade atteint de BPCO. Rev MalRespir 2010;27:522-48
4. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility,exercise performance and breathlessness in stable chronic obs-tructive pulmonary disease. Eur Respir J 1992;5:659-64
5. Bauerle O, Chrusch CA, Younes M. Mechanisms by whichCOPD affects exercise tolerance. Am J Respir Crit Care Med1998;157:57-68
6. Corbin RP, Loveland M, Martin RR, et al. A four-year follow-up study of lung mechanics in smokers. Am Rev Respir Dis1979;120:293-304
7. Perez T, Guenard H. Comment mesurer et suivre la dis-tension pulmonaire au cours de la BPCO Rev Mal Respir2009;26:381-93
8. Palacek F. Hyperinflation: control of functional residual lungcapacity. Physiol Res 2001;50:221-30
9. Sergysels R, Similowski T, Roche N. La distension doit-elle deve-nir la préoccupation principale de la prise en charge de laBPCO Rev Mal Respir 2008;25:1219-22
10. O'Donnell D. Implications cliniques de la distension thoracique,ou quand la physiopathologie change la prise en charge théra-peutique. Rev Mal Respir 2008;25:1305-18
11. Devillier P, Roche N. Pharmacological treatment of hyperinfla-tion. Rev Mal Respir 2009;26:613-24
12. Maury G, Marchand E. Distension thoracique et BPCO, au-delàde la mécanique respiratoire et de la dyspnée. Rev Mal Respir2009;26:153-65
13. Brouchet L, Thomas P, Renaud C, et al. Surgical mana-gement of COPD distension. Rev Mal Respir 2009;26:838-50
14. Perez Bogerd S, Selleron B, Hotton R, et al. Les techniques demédecine physique peuvent-elles pallier la distension Rev MalRespir 2009;26:1107-17
15. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airwayobstruction in chronic obstructive pulmonary disease. N Engl JMed 2004;350:2645-53
16. Ben Saad H, Ben Attia Saafi R, Rouatbi S, et al. Quelle définitionfaut-il choisir pour le déficit ventilatoire obstructif Rev MalRespir 2007;24:323-30
17. O'Donnell D, Webb KA. Exertional breathlessness in patientswith chronic airflow limitation. The role of lung hyperinflation.Am Rev Respir Dis 1993;148:1351-7
18. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capa-city, dynamic hyperinflation, breathlessness, and exerciseperformance during the 6-minute-walk test in chronic obs-tructive pulmonary disease. Am J Respir Crit Care Med2001;163:1395-9
19. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a betterpredictor of 5-year survival than airway obstruction in patientswith COPD. Chest 2002;121:1434-40
20. O'Donnell DE, D'Arsigny C, Fitzpatrick M, et al. Exercise hyper-capnia in advanced chronic obstructive pulmonary disease. AmJ Respir Crit Care Med 2002;166:663-8
21. O'Donnell D, Laveneziana P. The clinical importanceof dynamic lung hyperinflation in COPD. COPD 2006;3:219-32
22. Nguyen HQ, Altinger J, Carrieri-Kohlman V, et al. Factor ana-lysis of laboratory and clinical measurements of dyspnea inpatients with chronic obstructive pulmonary disease. J PainSymptom Manage 2003;25:118-27
23. O'Donnell D, Lam M, Webb KA. Measurement of symptoms,lung hyperinflation, and endurance during exercise in chro-nic obstructive pulmonary disease. Am J Respir Crit Care Med1998;158:1557-65
24. Casanova C, Cote C, de Torres JP, et al. The inspiratory to totallung capacity ratio predicts mortality in patients with COPD.Am J Respir Crit Care Med 2005;171:591-7
25. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosisof COPD in asymptomatic elderly never smokers. Eur Respir J2002;20:1117-22
26. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortalityin patients with emphysema and severe airflow obstruction.Am J Respir Crit Care Med 2006;173:1326-34
27. Maesen BL, Westermann CJ, Duurkens VA, et al. Effectsof formoterol in apparently poorly reversible chronicobstructive pulmonary disease. Eur Respir J 1999;13:1103-8
28. Ben Saad H, Préfaut C, Tabka Z, et al. The forgotten mes-sage from GOLD: FVC is a primary clinical outcome measureof bronchodilator reversibility in COPD. Pulm Pharmacol Ther2008;21:767-73
29. Ben Saad H, Ben Attia Saafi R, Rouatbi S, et al. Quelle définitionfaut-il choisir pour la réversibilité de l'obstruction bronchique Rev Mal Respir 2007;24:1107-15
30. Newton MF, O'Donnell DE, Forkert L. Response of lung volumesto inhaled salbutamol in a large population of patients withsevere hyperinflation. Chest 2002;121:1042-50
31. Wanger J, Clausen JL, Coates A, et al. Série du groupe de tra-vail ATS/ERS : standardisation des explorations fonctionnellesrespiratoires : standardisation de la mesure des volumes pul-monaires. Rev Mal Respir 2006;23 [17S47-17S60]
32. Fabbri LM, Boschetto P, Mapp CE. Global initiative for chro-nic obstructive lung disease; global initiative for asthmamanagement and prevention. COPD guidelines: the importantthing is not to stop questioning. Am J Respir Crit Care Med2007;176:527-8
33. Ben Saad H. Le narguilé et ses effets sur la santé. Partie I : lenarguilé, description générale et propriétés. Rev Pneumol Clin2009;65:369-75
34. Ben Saad H, Khemis M, Bougmiza I, et al. Profil spirométriquedes fumeurs de narguilé. Rev Mal Respir 2011;28:e39-51
35. Ben Saad H. Le narguilé et ses effets sur la santé. Par-tie II : les effets du narguilé sur la santé. Rev Pneumol Clin2010;66:132-44
36. Ben Saad H, Khemiss M, Bougmiza I, et al. Profil spirométriquedes fumeurs de narguilé. Rev Mal Respir 2009;26:299-314
37. Jenicek M, Cleroux R. Épidémiologie : principes techniques.Applications. Maloine, Paris: Edisem inc.; 1982 p. 430
38. Ferris BG, American Thoracic Society. Epidemiology stan-dardization project II: recommended respiratory diseasequestionnaires for use with adults and children in epidemio-logical research. Am Rev Respir Dis 1978;118:1-120
39. WHO 1997. World health organization: obesity: preventing andmanaging the global epidemic. Report of a WHO Consultation.World Health Organ Tech Rep Ser 2000;894:1-253
40. Miller MR, Hankinson J, Brusasco V, et al. Série du groupe detravail ATS/ERS : standardisation des explorations fonction-nelles respiratoires : standardisation de la spirométrie. RevMal Respir 2006;23 17S23-17S45
41. Tabka Z, Hassayoune H, Guenard H, et al. Spirome-tric reference values in a Tunisian population. Tunis Med1995;73:125-31
42. Ben Saad H, Tfifha M, Harrabi I, et al. Facteurs influençantles variables ventilatoires des Tunisiennes âgées de 45 ans etplus. Influence de la parité, de l'activité sportive, des don-nées anthropométriques et socioéconomiques. Rev Mal Respir2006;23:324-38
43. Pellegrino R, Viegi G, Brusasco V, et al. Série du groupede travail ATS/ERS : standardisation des explorations fonc-tionnelles respiratoires : stratégies d'interprétation desexplorations fonctionnelles respiratoires. Rev Mal Respir2006;23 [17S79-17S104]
44. Maltais F, Hamilton A, Marciniuk D, et al. Improve-ments in symptom-limited exercise performance over 8 hwith once-daily tiotropium in patients with COPD. Chest2005;128:1168-78
45. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oraltheophylline in severe chronic obstructive airways disease. BrMed J 1988;297:1506-10
46. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasonepropionate/salmeterol on lung hyperinflation and exerciseendurance in COPD. Chest 2006;130:647-56
47. Peters MM, Webb KA, O'Donnell DE. Combined physiologicaleffects of bronchodilators and hyperoxia on exertional dysp-noea in normoxic COPD. Thorax 2006;61:559-67
48. European respiratory society. Standardized lung function tes-ting. Eur Respir J 1993;19:1-95
49. Bougrida M, Ben Saad H, Kheireddinne Bourahli M, et al. Équa-tions de référence spirométriques des Algériens âgés de 19 à73 ans. Rev Mal Respir 2008;25:577-90
50. Stoks J, Quanjer PH. Reference values for residual volume,functional residual capacity and total lung capacity. ATSworkshop on lung volume measurements. Official statementof the European respiratory society. Eur Respir J 1995;8:492-506
51. O'Donnell D, Laveneziana P. Lung hyperinflation in COPD:the impact of pharmacotherapy. Eur Respir Rev 2006;15:85-9
52. O'Donnell D, Deesomchok A, Lam YM, et al. Effects of BMI onstatic lung volumes in patients with airway obstruction. Chest2011;140:461-8
53. Ghannem H, Hadj Fredj A. Habitudes alimentaires et facteursde risque cardiovasculaire. Étude épidémiologique au SahelTunisien. Presse Med 1999;28:1005-8
54. Franssen FM, O'Donnell DE, Goossens GH, et al. Obesity andthe lung: 5. Obesity and COPD. Thorax 2008;63:1110-7
55. Nagelmann A, Tonnov A, Laks T, et al. Lung dysfunction ofchronic smokers with no signs of COPD. COPD 2011;8:189-95
56. Sorino C, Battaglia S, Scichilone N, et al. Diagnosis of airwayobstruction in the elderly: contribution of the SARA study. IntJ Chron Obstruct Pulmon Dis 2012;7:389-95
57. Roberts SD, Farber MO, Knox KS, et al. FEV1/FVC ratio of 70 %misclassifies patients with obstruction at the extremes of age.Chest 2006;130:200-6
58. Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinfla-tion and its reversibility in patients with airway obstruction ofvarying severity. COPD 2010;7:428-37
59. Begin P, Grassino A. Inspiratory muscle dysfunction and chronichypercapnia in chronic obstructive pulmonary disease. Am RevRespir Dis 1991;143:905-12
60. Stanescu D, Veriter C. A normal FEV1/VC ratio does not excludeairway obstruction. Respiration 2004;71:348-52
61. O'Donnell D, Lam M, Webb KA. Spirometric correlates ofimprovement in exercise performance after anticholinergictherapy in COPD. Am J Respir Crit Care Med 1999;160:524-49
62. Hannink JD, van Helvoort HA, Dekhuijzen PN, et al. Dynamichyperinflation during daily activities: does COPD global initia-tive for chronic obstructive lung disease stage matter? Chest2010;137:1116-21
63. SPLF. Société de pneumologie de langue française. Actuali-sation 2003 des recommandations de la SPLF sur la prise encharge de la BPCO : organisation et argumentaire. Rev Mal Res-pir 2003;20:7-9
64. Celli B, ZuWallack R, Wang S, et al. Improvement in res-ting inspiratory capacity and hyperinflation with tiotropiumin COPD patients with increased static lung volumes. Chest2003;124:1743-8
65. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaledbronchodilators on inspiratory capacity and dyspnoea at restin COPD. Eur Respir J 2003;21:86-94
66. Hadcroft J, Calverley PM. Alternative methods for assessingbronchodilator reversibility in chronic obstructive pulmonarydisease. Thorax 2001;56:713-20
67. Calverley PMA. COPD: early detection and intervention. Chest2000;117:372-5.